Johnson & Johnson and Sanofi Announce Strategic Collaboration to Co-Develop First-in-Class ExPEC Vaccine for Invasive E. coli Disease in Adults Aged 60+-VCBeat

On October 3, Johnson & Johnson announced that it had reached a potential agreement with Sanofi.First-in-class ExPEC vaccine candidate reaches development and commercialization agreement for prevention of invasive E. coli disease (IED) in adults aged 60 and above, currently in Phase III E.mbrace study.

IED occurs when bacteria that normally live in the intestines leave the gut and infect other parts of the body. Severe infections, including bacteremia (blood infection) and sepsis, can occur, especially in adults over 60 years old, and may even be life-threatening. ExPEC is the main type of bacteria leading to sepsis.

This strategic agreement will combine Johnson & Johnson's R&D capabilities with Sanofi's global commercial vaccine expertise to jointly advance the ExPEC vaccine project. According to the terms of the agreement, both parties will share current and future R&D costs. Sanofi will pay Johnson & Johnson an upfront payment of $175 million and make additional payments upon reaching certain development and commercial milestones. In the United States, the EU Four (France, Germany, Italy, Spain), and the United Kingdom, the two companies will equally share profits.In the Rest of the World (ROW), Johnson & Johnson will receive a tiered royalty and sales milestone payments.

Penny Heaton, M.D., Global Therapeutic Area Head of Infectious Diseases and Vaccines at Johnson & Johnson, said: "We are committed to addressing the unmet need for an IED vaccine, a disease that affects nearly 10 million adults each year,And may lead to life-threatening infections, the current treatment options are very limited. This agreement will enable us to accelerate the development and potential commercialization process of this important preventive solution."

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship. Looking forward to your feedback.

Scan the QR code to provide valuable suggestions